Did you receive a mail about a class action on the settlement to resolve claims that Gilead Sciences pharmaceutical company delayed the release of a safer HIV/hepatitis B drug to prolong its profits from TDF drugs? This review will help you partake in the class action settlement after confirming the authenticity of the mail.
What Is TDF drugs may cause serious harm when taken for HIV or hepatitis B Class Action Settlement?
According to lawsuit against Gilead Sciences, the pharmaceutical company, which has made billions selling Viread, Truvada, Atripla, Complera and Stribild, knew that TDF drugs were “toxic to patients’ kidneys and bones.” Despite this knowledge, Gilead allegedly refused to research a safer alternative, tenofovir alafenamide fumarate (TAF).
Unlike TDF, TAF is effective at much lower doses, reducing the risk for serious side effects, such as bone injuries and kidney problems. Plaintiffs in the Truvada lawsuit claim that Gilead knew TAF was safer and more effective than TDF but shelved research on the drug to prolong profits from TDF’s patent.
“Gilead intentionally withheld a safer alternative design of TDF Drugs it knew to be dangerously toxic to patients’ kidneys and bones, while failing to adequately warn about the risks and safer use of the defective drugs, solely to make more money,” the TDF drug lawsuit contends.
What Is This Class Action All About?
Plaintiffs in a lawsuit claim they suffered serious consequences due to Gilead’s greed. One plaintiff allegedly suffered from bone demineralization after taking TDF drugs, eventually leading him to need a hip replacement. Another plaintiff suffered from bone damage and kidney failure due to TDF medications.
Patients who took Gilead’s TDF drugs and later developed kidney problems or bone injuries may be able to file a lawsuit and recover compensation for medical expenses, permanent disability, loss of earning capacity and more.
Gilead sells several TDF drugs including:
- Viread (TDF)
- Truvada (TDF/emtricitabine)
- Atripla (TDF/efavirenz/emtricitabine)
- Complera (TDF/emtricitabine/rilpivirine)
- Stribild (TDF/elvitegravir/cobicistat/emtricitabine)
Who Is Eligible?
The settlement benefits all class members who developed kidney or bone problems after taking TDF drugs for HIV or Hepatitis B.
How To Be Part of This Settlement
For a class member to partake in this settlement, they must submit their Valid claim on the settlement website.
What Is The Pay For This Settlement?
The pay for this settlement varies and the proof of purchase is not necessary.
Conclusion
As you submit your claim to the settlement website, just like Moda Insurance class action settlement we have reviewed , you’re doing so under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim.
